Latest Intelligence on Oncology in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: Avastin recommended for lung cancer in EU

Avastin has been backed by the European Committee for Medicinal Products for Human Use, for use as a first-line treatment in metastatic non-small cell lung cancer. As well as boosting Avastin's already blockbuster success, approval in this indication will also address some of the high unmet needs that persist in the disease.

Published By Datamonitor
24 Jul 2007
CommentWire
CommentWire

Roche: Avastin continues to march on

Roche has submitted a marketing authorization application to the European Medicines Agency for Avastin in previously untreated advanced breast cancer. This is yet more good news for Avastin, which, already approved in colorectal cancer, filed in non-small cell lung cancer and in phase III trials for hormone-refractory prostate cancer, is set to dominate the cancer market for years to come.

Published By Datamonitor
11 Jul 2006
CommentWire
CommentWire

Roche/Schering-Plough: interferon therapy shows potential

According to French research, certain types of B cell lymphoma respond to the hepatitis C immunotherapy, interferon alfa. While this isn't the first time HCV has been linked with lymphoma, the results should still persuade makers of interferon alfa drugs, such as Roche and Schering-Plough to investigate usage in this indication.

Published By Datamonitor
15 Jul 2002
Expert View
Expert View

Roche/Plexxikon: vemurafenib set to impact melanoma market

Roche and Plexxikon have submitted applications to the FDA and EMA for the approval of vemurafenib and a companion diagnostic in BRAF V600E mutation-positive metastatic melanoma. Approval of the drug is almost certain following impressive trial results and the addition of a companion diagnostic will enable Roche to dominate this segment of the melanoma market.

Published By Datamonitor
12 May 2011
CommentWire
CommentWire

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor
14 Apr 2003
Expert View
Expert View

Roche/Genentech/Biogen Idec: US approval will boost Rituxan dominance

The FDA has approved Rituxan for first-line maintenance treatment of patients with advanced follicular lymphoma that responded to initial treatment with Rituxan plus chemotherapy. Sales are expected to increase across the seven major markets following the FDA's decision and, as a result, Rituxan looks set to dominate in this indication.

Published By Datamonitor
02 Feb 2011
Expert View
Expert View

Roche/Genentech/Biogen Idec: Rituxan delays need for new therapy in follicular lymphoma

New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.

Published By Datamonitor
13 Dec 2010
CommentWire
CommentWire

Proteolix/Onyx Pharmaceuticals: Kyprolis recommendation may threaten Velcade in myeloma

The FDA's ODAC has recommended Kyprolis, the multiple myeloma treatment from Proteolix and Onyx Pharmaceuticals, despite ongoing cardiac and hepatic toxicity concerns. If approved, the drug will threaten Velcade's share of the myeloma market and could pose a threat to Johnson & Johnson's future revenues.

Published By Datamonitor
21 Jun 2012
CommentWire
CommentWire

Proteolix/Onyx Pharmaceuticals: Kyprolis approval is bad news for Velcade

Kyprolis, the multiple myeloma treatment from Proteolix and Onyx Pharmaceuticals, has received US approval a full week before the date set for the FDA's decision. With its high response rate and acceptable toxicity profile, Kyprolis will pose a serious threat to Velcade's position in the myeloma market.

Published By Datamonitor
24 Jul 2012
ResearchWire
ResearchWire

Prostate cancer: UK lowest for screening

Published By Datamonitor
17 Jan 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.